CQN-MA-RENAGADE
29.4.2024 23:01:34 CEST | Business Wire | Press release
Please replace the release dated April 26, 2024 with the following corrected version due to multiple revisions.
The updated release reads:
RENAGADE THERAPEUTICS CONTINUES COMMITMENT TO GANNA BIO AND GLYCAN BIOLOGY
GanNA founders include Carolyn Bertozzi, Ph.D., Richard D. Cummings, Ph.D., Ryan A. Flynn, M.D., Ph.D., and Namita Bisaria, Ph.D., M.B.A.
Additional investment strengthens ReNAgade’s delivery platform with unique conjugation platform based on novel glycobiology
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to unlock the potential of glycobiology through support for ongoing research at GanNA Bio, and an integration of the key founders of GanNA Bio into the ReNAgade ecosystem.
GanNA Bio was formed in 2021 and invested in by ReNAgade to harness novel glycobiology to enable extra-hepatic RNA delivery based on pioneering research licensed from Stanford University, Boston Children’s Hospital, and Beth Israel Deaconess Medical Center, which was developed in the labs of Carolyn Bertozzi, Ph.D., winner of the 2022 Nobel Prize in Chemistry and Professor of Chemistry in the Stanford School of Humanities and Sciences; Ryan A. Flynn, M.D., Ph.D., Assistant Professor at Boston Children’s Hospital; and Richard D. Cummings, Ph.D., S. Daniel Abraham Professor of Surgery at Beth Israel Deaconess Medical Center, and led by Namita Bisaria, Ph.D., M.B.A., a serial entrepreneur in the RNA therapeutics field. Its platform, based on new advances in glycobiology and synthesis, uses cell-specific glycans to develop next-generation conjugates and to unlock the delivery of short and long stranded RNA medicines.
“ReNAgade will continue to benefit tremendously from GanNA’s promising work in developing extra-hepatic delivery technology that helps expand the breadth and potential of our own RNA medicines,” said Brian Goodman, Co-founder of ReNAgade. “Delivery is foundational to ReNAgade’s mission to overcome the current limitations of RNA medicines. We believe the technology developed within GanNA will help further solidify ReNAgade’s leadership position as we continue advancing our unique, integrated therapeutic platform.” GanNA founders Bertozzi and Cummings will now serve as advisors to ReNAgade.
“The progress in glycoRNA science from our seminal publication in the journal Cell is moving fast, and integration with ReNAgade’s pipeline will strengthen our position to develop a broad portfolio of cell specific delivery systems, leveraging the latest developments in glycobiology in order to expand the array of addressable diseases of RNA medicines,” said Ryan Flynn.
Dr. Bertozzi added, “The combination of GanNA’s innovative glycobiology-based targeting strategy with ReNAgade’s experience in the development of RNA medicines will be a powerful combination for the benefit of patients.” Dr. Cummings noted that “Glycobiology-based RNA medicines represent a new frontier, and it is rewarding to see the possibilities of ReNAgade developing these for clinical use.”
About ReNAgade Therapeutics
ReNAgade exists to unlock the potential for RNA medicines to treat disease anywhere in the body. We combine our novel RNA delivery platforms with a comprehensive RNA platform allowing for an all-RNA system for coding, editing, and gene insertion to develop new medicines.
To accelerate the future of medicine, we bring together a team with deep RNA and delivery expertise to develop paradigm-shifting RNA medicines.
ReNAgade Therapeutics—RNA Without Limits
For more information about the company, its technologies, and its leadership, visit www.renagadetx.com
About GanNA Bio
GanNA was created by Drs. Flynn and Bisaria, and invested by ReNAgade in 2021 following a sponsored research agreement in the lab of Dr. Flynn. The mission is to explore the potential of novel glycobiology therapies following the pioneering work at Stanford University by Drs. Flynn and Bertozzi on glycoRNA. The GanNA Bio Scientific Advisory Board included Drs. Bertozzi, Cummings, Flynn, and ReNAgade CSO, Pete Smith.
University Conflict of Interest Disclosure
Drs. Bertozzi, Cummings and Flynn consult for ReNAgade Therapeutics.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240426251202/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Comwrap Reply Recognized With the Adobe CXO Emerging Partner Western Europe Award21.4.2026 09:52:00 CEST | Press release
Comwrap Reply, the Reply company specialised in cloud-native digital experience services, has received the Adobe CXO Emerging Partner Western Europe Award, one of the recognitions presented as part of the Adobe Customer Experience Orchestration Partner Awards, which honour companies that have made significant contributions to Adobe’s business and delivered a tangible impact on customer success. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260421234434/en/ The award is part of a long-standing collaboration with Adobe, recently reaffirmed by the renewal of Comwrap Reply’s Adobe Platinum Solution Partner status, and highlights the experience gained in developing digital experience solutions on Adobe Experience Cloud. The recognition confirms Comwrap Reply’s role in supporting organisations in the design and evolution of digital platforms based on Adobe Experience Cloud, capable of integrating content, data and customer journe
Lenovo Brings Production-Scale AI to Hannover Messe 2026, Delivering Up to 85% Faster Lead Times for Manufacturers21.4.2026 09:00:00 CEST | Press release
With 94% of manufacturers increasing AI investment in 2026, Lenovo enables the shift from pilot to production with solutions already delivering measurable gains in cost, quality, and operational performance Manufacturers are under increasing pressure to improve efficiency, resilience, and responsiveness in the face of ongoing supply chain volatility and rising operational complexity. In this environment, AI is no longer a future ambition but an operational necessity. With 94% planning to increase AI investment in 20261 and an expected $2.86 return for every dollar spent2, the priority has shifted from experimentation to execution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260421992136/en/ ThinkStation PGX and Lenovo ThinkEdge Solution 2 At Hannover Messe 2026, Lenovo in partnership with NVIDIA are demonstrating how manufacturers can close that gap by deploying AI solutions already proven at scale across its own global o
Barnes Molding Solutions Becomes SPECTRIX21.4.2026 07:00:00 CEST | Press release
Barnes Molding Solutions is now SPECTRIX. The new Brand offers the full Spectrum of injection molding capabilities delivered by its leading brands - Männer, Foboha, Synventive, Priamus, Thermoplay, and Gammaflux. The change, announced at Chinaplas 2026, reflects the integration of core technologies within a single organization: part design, material science, hot runner and mold technology, sensors & controls and injection molding. Day-to-day operations remain unchanged, including contacts, contracts, and processes. Focused on global growth Under President Marcello Vendemiati, SPECTRIX is strengthening its global market focus and expanding its footprint. This strategy is already visible with the opening of a new manufacturing facility in Pune, India. Another production site near Detroit, USA, is set to open soon. The name SPECTRIX combines “spectrum” and “plastics,” while reflecting the company’s core strengths: expertise, experience, and excellence. Its tagline, “Enduring Advantage, En
Bringg Welcomes Chris Conway as Senior Vice President and General Manager, EMEA21.4.2026 07:00:00 CEST | Press release
Conway, who scaled one of the UK’s largest delivery operations as a Bringg customer, joins to lead the company’s European expansion Bringg, the last-mile performance leader, today announced Chris Conway's appointment as Senior Vice President and General Manager, EMEA. Conway will lead Bringg's commercial strategy, customer relationships, and go-to-market operations across the region. Conway brings more than 20 years of experience in eCommerce, digital commerce, and operational transformation at three of the UK's largest grocery retailers. Most recently, he served as Managing Director of Quick Commerce and Food Operating Board Member at Co-op, where he built and scaled a £500 million-plus q-commerce operation delivering from nearly 2,000 stores. He also founded Peckish, a rapid delivery app that gave independent retailers access to q-commerce technology. He also led Asda's online grocery business to more than £1 billion in revenue and 20% market share, and ran the online commercial team
Edge Home Finance Announces Strategic Investment from Presidio Investors and Promotion of Tom Ahles to President21.4.2026 06:06:00 CEST | Press release
Edge Home Finance today announced a strategic investment from Presidio Investors (“Presidio”), marking a major milestone in the company’s continued expansion and leadership within the mortgage broker channel. As part of this transaction, Tom Ahles has been promoted to President of Edge Home Finance, reinforcing the company’s commitment to strong leadership as it enters its next phase of growth. The investment from Presidio represents a powerful alignment focused on accelerating Edge’s momentum through enhanced investment in technology, operational infrastructure, and strategic acquisitions. Presidio brings a track record of partnering with high-growth companies and scaling them through disciplined capital deployment and operational expertise. “This strategic investment is a direct reflection of the strength of our platform and the momentum we’ve built,” said Tom Ahles, President of Edge Home Finance. “With Presidio’s backing, we are positioned to move faster, invest more aggressively i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom